LXRX 2.06 Lexicon Pharmaceuticals, Inc.
| Range: | 0.92-3.73 | Vol Avg: | 2828357 | Last Div: | 0 | Changes: | 0.05 |
| Beta: | 1.29 | Cap: | 0.63B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Apr 07 2000 | Empoloyees: | 285 | ||
| CUSIP: | 528872302 | CIK: | 0001062822 | ISIN: | US5288723027 | Country: | US |
| CEO: | Dr. Michael Exton Ph.D. | Website: | https://www.lexpharma.com | ||||
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow